Probably Genetic Raised $12 Million Series A
The biotech startup secured new funding to support its expansion into the drug discovery market.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust AI platforms to accurately identify rare diseases through self-reported health data?
Probably Genetic has raised $12 million in a series A funding round led by Threshold. The company plans to use the capital to hire staff and enter the drug discovery space.
Why it matters
By leveraging its large dataset of 130,000 patients, the company intends to help pharmaceutical partners identify candidates for clinical trials. This move marks the startup's transition from a testing-focused firm to an active participant in drug development.
The company utilizes an AI platform to integrate self-reported symptoms, medical records, and biological data. To date, they have collected data from 130,000 patients and maintain a $250 cap on patient copays for testing.
The players
Probably Genetic
This biotech firm collects patient data to facilitate medical testing and drug discovery efforts.
Threshold
This investment firm led the company's latest series A funding round.
ARPA-H
This federal agency awarded the company up to $10 million in funding in August 2026.
The details
Founded in 2018, the company operates without its own labs, instead utilizing external partners for genetic sequencing. It currently participates in the RAPID program and holds partnerships with entities including UCB, Biogen, and Ultragenyx.
Timeline
2018: Probably Genetic was founded.
August 2026: Company awarded up to $10 million from ARPA-H.
October 14, 2026: Company announced $12 million series A funding.
2027: Company plans to expand to proteomic testing.
The Tech Race
The firm follows a pattern of utilizing federal support from the Advanced Research Projects Agency for Health (ARPA-H) to scale its specialized diagnostic data platform. This shift highlights a broader industry trend where diagnostic startups use massive patient datasets to become essential gateways for clinical trial recruitment.
Patients may find easier access to specialized testing through the company's partnerships, with out-of-pocket costs typically limited to $250. This expansion could eventually lead to more personalized treatment options as the company begins identifying patients for new clinical trials.
The takeaway
The company's pivot toward drug discovery represents a significant consolidation of patient data in the clinical trial pipeline. Patients should be aware that participating in such testing platforms may involve the sharing of sensitive medical information with pharmaceutical partners.
What happens next
The company is scheduled to expand its diagnostic capabilities into proteomic testing in 2027.
Further reading
For more information on current developments in the sector, see Biotech.
Source note: This article includes information reported by FierceHealth.
Live Poll
Do you trust AI platforms to accurately identify rare diseases through self-reported health data?
